294 related articles for article (PubMed ID: 26681198)
1. Fluocinolone acetonide for the treatment of diabetic macular edema.
Haritoglou C; Mayer W; Wolf A
Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
[TBL] [Abstract][Full Text] [Related]
2. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
3. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
Campochiaro PA; Hafiz G; Shah SM; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane F;
Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
5. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
6. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
[TBL] [Abstract][Full Text] [Related]
7. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
[TBL] [Abstract][Full Text] [Related]
8. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
9. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
11. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
12. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
Adams OE; Schechet SA; Hariprasad SM
Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
[TBL] [Abstract][Full Text] [Related]
13. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants.
Parrish RK; Traverso CE; Green K; Danis RP;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):418-25. PubMed ID: 27183545
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal steroids for macular edema in diabetes.
Grover D; Li TJ; Chong CC
Cochrane Database Syst Rev; 2008 Jan; (1):CD005656. PubMed ID: 18254088
[TBL] [Abstract][Full Text] [Related]
16. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
17. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.
Messenger WB; Beardsley RM; Flaxel CJ
Drug Des Devel Ther; 2013; 7():425-34. PubMed ID: 23737661
[TBL] [Abstract][Full Text] [Related]
18. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
20. Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema.
Puliafito CA; Cousins SW; Bacharach J; Gonzalez VH; Holekamp NM; Merrill PT; Ohr MP; Parrish RK; Riemann CD
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4-S15. PubMed ID: 27096289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
